These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33196346)

  • 1. pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression.
    Chevallier E; Jouve T; Rostaing L; Malvezzi P; Noble J
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):55-66. PubMed ID: 33196346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors.
    Wyzgał J; Paczek L; Sańko-Resmer J; Ciszek M; Nowak M; Rowiński W; Szmidt J; Durlik M
    Ann Transplant; 2007; 12(2):26-9. PubMed ID: 18173063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant diabetes mellitus: the last 10 years with tacrolimus.
    Bäckman LA
    Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi13-vi16. PubMed ID: 15575021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive drug-induced diabetes.
    Penfornis A; Kury-Paulin S
    Diabetes Metab; 2006 Dec; 32(5 Pt 2):539-46. PubMed ID: 17130815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression and Post-transplant Hyperglycemia.
    Montero N; Pascual J
    Curr Diabetes Rev; 2015; 11(3):144-54. PubMed ID: 25824238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression.
    Baron PW; Infante S; Peters R; Tilahun J; Weissman J; Delgado L; Kore AH; Beeson WL; de Vera ME
    Ann Transplant; 2017 May; 22():309-314. PubMed ID: 28533501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management.
    First MR; Gerber DA; Hariharan S; Kaufman DB; Shapiro R
    Transplantation; 2002 Feb; 73(3):379-86. PubMed ID: 11884934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis.
    Oliveras L; Coloma A; Lloberas N; Lino L; Favà A; Manonelles A; Codina S; Couceiro C; Melilli E; Sharif A; Hecking M; Guthoff M; Cruzado JM; Pascual J; Montero N
    Transplant Rev (Orlando); 2024 Jul; 38(3):100856. PubMed ID: 38723582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal posttransplantation diabetes mellitus: An overview.
    Pimentel AL; Bauer AC; Camargo JL
    Clin Chim Acta; 2015 Oct; 450():327-32. PubMed ID: 26368267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.
    Cosio FG; Pesavento TE; Osei K; Henry ML; Ferguson RM
    Kidney Int; 2001 Feb; 59(2):732-7. PubMed ID: 11168956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression.
    Veroux M; Corona D; Giuffrida G; Gagliano M; Sorbello M; Virgilio C; Tallarita T; Zerbo D; Giaquinta A; Fiamingo P; Macarone M; Li Volti G; Caglia P; Veroux P
    Transplant Proc; 2008; 40(6):1885-7. PubMed ID: 18675079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?
    Choi JY; Kwon OJ
    Transplant Proc; 2013 Oct; 45(8):2892-8. PubMed ID: 24156999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids use in kidney transplant setting.
    De Lucena DD; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1023-1041. PubMed ID: 30265586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Hricik DE; Anton HA; Knauss TC; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2002 Jul; 74(2):189-93. PubMed ID: 12151730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
    Sommerer C; Witzke O; Lehner F; Arns W; Reinke P; Eisenberger U; Vogt B; Heller K; Jacobi J; Guba M; Stahl R; Hauser IA; Kliem V; Wüthrich RP; Mühlfeld A; Suwelack B; Duerr M; Paulus EM; Zeier M; Porstner M; Budde K;
    BMC Nephrol; 2018 Sep; 19(1):237. PubMed ID: 30231851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.